HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 661-672 of 4,505
Behavioral study icon
CompletedNCT01521026

Cognitive Training for people with Schizophrenia

Official study title

Cognitive Training for Patients With Schizophrenia

This study has finished and is no longer accepting participants.

In San Diego
SchizophreniaBehavioural studyAges 18–65
Countries
United States
Sponsor
University of California, San Diego
Drug study icon
TerminatedNCT01368458

Conversion to Antipsychotic Monotherapy

Official study title

A Randomized, Rater-Blind, Controlled, Clinical Trial of Conversion to Antipsychotic Monotherapy vs. Continued Polypharmacy for Patients With Schizophrenia or Schizoaffective Disorder

This study ended early.

Location not clearly listed
SchizophreniaInterventional studyAges 18–75
Countries
Sponsor
Nathan Kline Institute for Psychiatric Research
Drug study icon
CompletedNCT04268303

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

What is this study about?

Researchers compared Sublingual film containing dexmedetomidine (BXCL501) and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–75
Countries
United States
Sponsor
BioXcel Therapeutics Inc
Drug study icon
CompletedNCT00159770

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Official study title

Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.

This study has finished and is no longer accepting participants.

Multiple locations, including Aalborg
SchizophreniaMedication studyAges 18+
Countries
Switzerland, Denmark, Finland, + 1 other
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
CompletedNCT01074632

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Official study title

A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Sumitomo Pharma America, Inc.
Drug study icon
CompletedNCT01198353

Effectiveness of Ziprasidone for people with Schizophrenia

What is this study about?

This study evaluated the effectiveness of Ziprasidone for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Ansan
SchizophreniaMedication studyAges 18–55
Countries
South Korea
Sponsor
Soonchunhyang University Hospital

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.